How big is Jazz Pharmaceuticals Plc?

As of Jun 18, Jazz Pharmaceuticals Plc has a market capitalization of 6,477.70 million, with net sales of 4,064.81 million and net profit of 482.21 million over the latest four quarters. Shareholder's funds are 4,093.76 million, and total assets amount to 12,012.26 million.

As of Jun 18, Jazz Pharmaceuticals Plc has a market capitalization of 6,477.70 million, categorizing it as a Mid Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 4,064.81 million, while the sum of Net Profit for the same period is 482.21 million.<BR><BR>As of Dec 24, the reporting period shows Shareholder's Funds at 4,093.76 million and Total Assets at 12,012.26 million.

What does Jazz Pharmaceuticals Plc do?

Jazz Pharmaceuticals Plc is a biopharmaceutical company focused on developing products for unmet medical needs. As of March 2025, it reported net sales of $898 million and a net profit of -$93 million, with a market cap of $6.48 billion.

Overview: <BR>Jazz Pharmaceuticals Plc is a biopharmaceutical company focused on developing and commercializing products that address unmet medical needs in the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 898 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -93 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 6,477.70 Million (Mid Cap)<BR><BR>Key Metrics: <BR>P/E: 14.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.67 <BR>Return on Equity: 11.59% <BR>Price to Book: 1.55<BR><BR>Contact Details: <BR>Address: Fifth Fl, Waterloo Exchange, Waterloo Road DUBLIN None : 4 <BR>Tel: ['353 1 6347800', '1 650 4962800'] <BR>Fax: 353 1 6347850 <BR>Website: https://www.jazzpharma.com/

Who are in the management team of Jazz Pharmaceuticals Plc?

As of March 2022, the management team of Jazz Pharmaceuticals Plc includes Chairman and CEO Bruce Cozadd, Directors Jennifer Cook and Mark Smith, and Independent Directors Paul Berns, Patrick Enright, and Peter Gray. They are responsible for the company's strategic direction and operations.

As of March 2022, the management team of Jazz Pharmaceuticals Plc includes the following individuals:<BR><BR>- Mr. Bruce Cozadd, who serves as the Chairman of the Board and Chief Executive Officer.<BR>- Ms. Jennifer Cook, who is a Director.<BR>- Dr. Mark Smith, also a Director.<BR>- Mr. Paul Berns, who holds the position of Independent Director.<BR>- Mr. Patrick Enright, another Independent Director.<BR>- Mr. Peter Gray, who is also an Independent Director. <BR><BR>This team plays a crucial role in guiding the company's strategic direction and operations.

Should I buy, sell or hold Jazz Pharmaceuticals Plc?

Is Jazz Pharmaceuticals Plc overvalued or undervalued?

As of August 5, 2025, Jazz Pharmaceuticals Plc is considered overvalued with a P/E ratio of 14 compared to the peer average of 16.11, a PEG ratio of 0.68 indicating reasonable growth potential, and mixed performance results, including a 1-year stock return of 19.74% versus the S&P 500's 17.14%, but a disappointing 3-year return of -11.05% compared to the S&P 500's 70.41%.

As of 5 August 2025, Jazz Pharmaceuticals Plc has moved from an attractive to a risky valuation grade. The company appears to be overvalued, as indicated by its P/E ratio of 14, which is lower than the peer average of approximately 16.11, and a PEG ratio of 0.68, suggesting potential growth at a reasonable price compared to its peers. Additionally, the EV to EBITDA ratio stands at 7.69, which is more favorable than some peers like Neurocrine Biosciences, Inc. with an EV to EBITDA of 25.28, but still reflects a concern given the overall risk profile.<BR><BR>In terms of peer comparison, Jazz Pharmaceuticals is positioned against companies like Viatris, Inc., which has a P/E ratio of 44.86, and Neurocrine Biosciences, Inc., which has a significantly higher P/E of 37.08. While Jazz has shown a 1-year stock return of 19.74%, outperforming the S&P 500's 17.14%, its longer-term performance has been underwhelming, with a 3-year return of -11.05% compared to the S&P 500's 70.41%. This mixed performance further supports the view that the stock is currently overvalued.

Is Jazz Pharmaceuticals Plc technically bullish or bearish?

As of August 18, 2025, Jazz Pharmaceuticals Plc shows a mildly bullish trend supported by positive indicators like a bullish MACD and moving averages, despite mixed signals from Dow Theory and underperformance in longer-term periods.

As of 18 August 2025, the technical trend for Jazz Pharmaceuticals Plc has changed from sideways to mildly bullish. Key indicators supporting this stance include a bullish MACD on both the weekly and monthly time frames, bullish Bollinger Bands, and a bullish daily moving average. However, the Dow Theory presents a mixed view with a mildly bearish weekly signal and a mildly bullish monthly signal. The stock has outperformed the S&P 500 over the past week and month, returning 2.13% and 11.49% respectively, while it has lagged behind in the year-to-date and longer-term periods. Overall, the current technical stance is mildly bullish, driven by positive momentum in several indicators despite some mixed signals.